In summary, S12, which is a first-generation dual RAGE/SERT inhibitor, has demonstrated the viability of the pharmacophore fusion strategy and offered a useful prototype for the possible treatment of AD with comorbid depression [49]. Here, SLC6A4 is linked to Alzheimer disease.